Complete Story
 

02/03/2021

Amgen’s Biosimilar RIABNI™ (rituximab-arrx) Now Available

Continuing our four decades of experience in biologics development, Amgen is proud to announce the availability of our latest biosimilar RIABNI™ (rituximab-arrx). Please click the link below to see full Prescribing Information, including Boxed WARNINGS:

RIABNI™ Prescribing Information 

The Wholesale Acquisition Cost (WAC) of RIABNI™ will be 23.7% lower than the reference product.  RIABNITM is being made available at a WAC of $716.80 per 100 mg and $3,584.00 per 500 mg single-dose vial, 23.7% less than the WAC for Rituxan®, 15.2% less than the WAC for TRUXIMA®, and matching the WAC for RUXIENCE®.  At launch, RIABNITM is priced 16.7% below the current Rituxan® Average Selling Price (ASP).

RIABNI™ will be available from both wholesalers and specialty distributors.

Additionally, the following Healthcare Common Procedure Coding System (HCPCS) and National Drug Codes (NDC) have been assigned:

RIABNI™:

  • Hospital HCPCS = C9399 (unclassified drugs or biologics)
  • Clinic HCPCS = J3590 (unclassified biologic)
  • NDC 55513-224-01, 100 mg single-dose vial of RIABNI™
  • NDC 55513-326-01, 500 mg single-dose vial of RIABNI™

RIABNITM is administered as an intravenous infusion.

RIABNI™ Product Fact Sheet.

Printer-Friendly Version



Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it! 
Report Broken Link